Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib plus cisplatin/pemetrexed versus cisplatin/pemetrexed in malignant mesothelioma
NL-OMON33544Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of axitinib, cisplatin and pemetrexed in mesothelioma and pleural mesothelioma (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Tissue effects of axitinib addition and Safety. Started Dec 2008; status: recruiting.
02
Drugs
axitinibcisplatinpemetrexed
03
Conditions
mesotheliomapleural mesothelioma
Beyond the preview
Go deeper on NL-OMON33544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33544.